Tag: data

Explore the Phenylketonuria Therapeutics market with our comprehensive report, detailing current and future competition. Discover key trends, pipeline developments, and market dynamics shaping the PKU landscape through data-driven insights and expert analysis. Stay ahead in this evolving therapeutic domain.

Basel, Switzerland – June 18, 2025 - TOLREMO therapeutics AG (TOLREMO), a clinical-stage biotechnology company developing TT125-802, a best-in-class CBP/p300 bromodomain inhibitor for the treatment of solid tumors and multiple myeloma, today announced key leadership appointments. Alessandra Cesano, MD, PhD, who has served as Consulting Chief Medical Officer since April 2023, will join the company’s Board of Directors. Florian D. Vogl, MD, PhD, has been appointed as Chief Medical Officer (CMO), succeeding Alessandra Cesano on the executive team.

SHANGHAI, June 18, 2025 (GLOBE NEWSWIRE) -- The 33^rd China International Bicycle Fair (CHINA CYCLE 2025 in abbreviation), with the theme “New Quality Productivity for the Shared Future”, has been grandly held from May 5^th to 8^th, 2025 at Shanghai New International Expo Center. This exhibition keeps pace with the times and has once again achieved breakthroughs in scale and content, creating a diverse and colorful display environment for exhibitors, buyers and visitors. The service quality of the exhibition has also been improved, and a more complete international bicycle industry trade platform has been built. Chinese and foreign mainstream media and industry media, including CCTV and Xinhuanet, have reported on the CHINA CYCLE.

Privacy-first, AI-ready data collaboration delivers smarter media planning and measurement for advertisers across TV, streaming, and digital media

Cardiff, United Kingdom – 18 June 2025 – Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, today launches from stealth having raised a total of $140 million (£107 million) in the last nine months. The oversubscribed Series A financing was led by Access Biotechnology, with participation from Canaan Partners, SR One, Sanofi Ventures, Schroders Capital along with seed investors SV Health Investors, which co-founded the company, and ICG.

Learn key insights from the 2025 "State of the Air" report and how Camfil’s IAQ solutions address air quality challenges for healthier indoor spaces.